AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

- 1. (Currently amended) A method of screening a compound or its salt that changes the bindingproperty of a G protein-coupled receptor-protein-comprising: the same or substantially the same amino acid sequence as the amino acid sequence represented by SEO ID NO: 1, SEO ID NO: 3 or SEQ ID NO: 8, or a salt thereof, to a fatty acid or a salt thereof, which comprises using (1)the receptor protein, its partial pentide, or a salt thereof and (2) the fatty acid or a salt thereof (i) contacting in vitro cells comprising a G protein-coupled receptor protein comprising substantially the same amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 8, wherein the G protein-coupled receptor protein has a G protein-coupled receptor function, with a fatty acid or a salt thereof in the presence of the compound or its salt and in the absence of the compound or its salt,
- (ii) assaying a cell-stimulating activity stimulated by binding of the fatty acid or a salt thereof to the G protein-coupled receptor protein in the presence of the compound or its salt and in the absence of the compound or its salt, and
- (iii) comparing the cell-stimulating activity stimulated by binding of the fatty acid or a salt thereof to the G protein-coupled receptor protein in the presence of the compound or its salt and in the absence of the compound or its salt, wherein a change in cell-stimulating activity indicates that the compound or its salt changes a binding property of the G protein-coupled receptor protein.

2. (Canceled)

Attorney Docket No. 10577.0004-00000

Application No.: 10/542,408

3. (Currently Amended) A method of Claim 1 for screening an agonist or an antagonist to a G-

protein-coupled receptor protein comprising the same or substantially the same amino acid-

sequence as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID

NO: 8, or a salt thereof, which comprises using (1) the receptor protein, its partial peptide, or a

salt thereof and (2) a compound or its salt that changes the binding property of the receptor-

protein, or a salt thereof to a fatty acid or a salt thereof, a compound or its salt comprising:

i) contacting in vitro a G protein-coupled receptor protein comprising substantially the same

amino acid sequence represented by SEQ ID NO: I, SEQ ID NO: 3 or SEQ ID NO: 8, wherein

the G protein-coupled receptor protein has a G protein-coupled receptor function, with a fatty

acid or a salt thereof in the presence of the compound or its salt and in the absence of the

compound or its salt,

ii) assaying the binding of the fatty acid or a salt thereof to the G protein-coupled receptor

protein in the presence of the compound or its salt and in the absence of the compound or its salt.

<u>and</u>

iii) comparing the binding of the fatty acid or a salt thereof to the G protein-coupled receptor

protein in the presence of the compound or its salt and in the absence of the compound or its salt,

wherein a change in binding indicates that the compound or its salt changes a binding property of

the G protein-coupled receptor protein.

4.-13. (Canceled)

3

14. (Currently Amended) [[A]] The method of Claim claim 1, for screening an agonist to a Gprotein-coupled receptor protein comprising the same or substantially the same amino acidsequence as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 3 or SEQ IDNO: 8, or a salt thereof, which comprises assaying wherein the cell-stimulating activity is at least
one selected from [[the]] intracellular Ca²⁺ level increasing activity, [[the]] intracellular cAMP
production suppressing activity, MAP kinase phosphorylation or activation, [[the]]
adrenocorticotropic hormone (ACTH) secretion suppressing activity, [[the]] glycerol production
suppressing activity or [[the]] lipolysis suppressing activity, in the ease where a test-compound is
contacted with cells containing a G-protein-coupled receptor protein comprising the same or
substantially the same amino acid sequence as the amino acid sequence represented by SEQ IDNO: 1, SEQ ID NO: 3 or SEQ ID NO: 8, or a salt thereof.

15.-77. (Canceled)

- 78. (New) The method of claim 1, wherein the compound is an agonist or antagonist to a G protein-coupled receptor protein.
- 79. (New) The method of claim 3, wherein the compound is an agonist or antagonist to a G protein-coupled receptor protein.
- 80. (New) The method of claim 14, wherein the compound is an agonist or antagonist to a G protein-coupled receptor protein.